{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:47:50Z","timestamp":1777553270914,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p>\n                    Lipohypertrophy in HIV-infected patients is associated with metabolic abnormalities. Raltegravir (RAL) is not known to induce fat changes or severe metabolic perturbations. HIV-infected women with central adiposity and HIV-1 RNA less than 50 copies per milliliter on non-nucleoside reverse transcriptase inhibitor (NNRTI)- or protease inhibitor (PI)-based antiretroviral therapy (ART) continued their nucleoside reverse transcriptase inhibitor (NRTI) backbone and were randomized to switch to open label RAL immediately or after 24 weeks. The primary end point was 24-week between-group change in computed tomography (CT)-quantified visceral adipose tissue (AT) volume. Fasting lipids, glucose, C-reactive protein (CRP), anthropometric measurements, and patient-reported quality of life assessments were also measured. Thirty-six subjects provided 80% power to detect a 10% between-group difference in visceral AT over 24 weeks. Thirty-seven of 39 enrolled subjects completed week 24. At entry, subjects were 75% black or Hispanic, and on 62% PI-based and 38% NNRTI-based regimens. The median age was 43 years, CD4 count 558 cells per microliter, and body mass index (BMI) 32 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . After 24 weeks, no statistically significant changes in visceral or subcutaneous AT, anthropometrics, BMI, glucose, or CRP were observed. In subjects receiving RAL, significant improvements in total and LDL cholesterol (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.04), self-reported belly size (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.02) and composite body size (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.02) were observed. Body size changes correlated well with percent visceral AT change. No RAL-related adverse events occurred. Compared to continued PI or NNRTI, switch to RAL was associated with statistically significant 24-week improvements in total and LDL cholesterol but not AT volumes. Additional insights into AT and metabolic changes in women on RAL will be provided by 48-week follow-up of the immediate-switch arm.\n                  <\/jats:p>","DOI":"10.1089\/apc.2012.0135","type":"journal-article","created":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T14:47:45Z","timestamp":1343054865000},"page":"532-540","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy"],"prefix":"10.1177","volume":"26","author":[{"given":"Jordan E.","family":"Lake","sequence":"first","affiliation":[{"name":"University of California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace A.","family":"McComsey","sequence":"additional","affiliation":[{"name":"Case Western Reserve University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"Hulgan","sequence":"additional","affiliation":[{"name":"Vanderbilt University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine A.","family":"Wanke","sequence":"additional","affiliation":[{"name":"Tufts University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Mangili","sequence":"additional","affiliation":[{"name":"Tufts University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L.","family":"Walmsley","sequence":"additional","affiliation":[{"name":"University of Toronto","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Sean","family":"Boger","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph R.","family":"Turner","sequence":"additional","affiliation":[{"name":"Phase V Technologies, Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather E.","family":"McCreath","sequence":"additional","affiliation":[{"name":"University of California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith S.","family":"Currier","sequence":"additional","affiliation":[{"name":"University of California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,9,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00631.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0587"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318164227f"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31816d9ba1"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(87)90063-1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31814b94e2"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.8.2087"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2009.0191"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2006.128"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2006.20.6"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/430379"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832b4377"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181142d26"},{"key":"e_1_3_3_15_2","first-page":"199","article-title":"Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India","volume":"39","author":"Pujari SN","year":"2005","unstructured":"Pujari SN, , Dravid A, , Naik E et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr, 2005; 39:199\u2013202.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318158c0a6"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318186521a"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1310\/hct1202-89"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/31.5.1016"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309010-00008"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/597776"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328270356a"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir324"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62041-9"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181da1287"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60918-1"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072375"},{"key":"e_1_3_3_28_2","first-page":"L56","article-title":"The impact of recombinant human growth hormone (r-hGH) on body image and health-related quality of life (HRQOL) in patients with HIV-associated adipose redistribution syndrome (HARS)","volume":"11","author":"Turner R","year":"2006","unstructured":"Turner R. The impact of recombinant human growth hormone (r-hGH) on body image and health-related quality of life (HRQOL) in patients with HIV-associated adipose redistribution syndrome (HARS) Antiviral Ther, 2006; 11:L56.","journal-title":"Antiviral Ther"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834f3507"},{"key":"e_1_3_3_30_2","first-page":"402","volume-title":"Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections","author":"Saumoy MOJ","year":"2011","unstructured":"Saumoy MOJ, , Martinez E, , Llibre J, , Ribera E, , Knobel H. Podzamczer D Comprehensive lipid evaluation in patients switching from PI\/r-based cART to a RAL-based cART: The SPIRAL Substudy. Abstracts from the 18th Conference on Retroviruses and Opportunistic InfectionsFebruary 27March 2, 2011, Boston, MA, 2011; 402."}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/apc.2012.0135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/apc.2012.0135","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/apc.2012.0135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:01:11Z","timestamp":1777399271000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/apc.2012.0135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1089\/apc.2012.0135"],"URL":"https:\/\/doi.org\/10.1089\/apc.2012.0135","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}